CD274 and cancer: This hypothesis was further supported by Yi, et al., 2020 in regulating PD-L1 mediated HNSCC control by implicating m6A-modifiers, and thus potentiating its therapeutic value by targeting G2M checkpoint, mTORC1 and PI3K/AKT/mTOR signaling analyzed via cancer genome atlas TCGA (n = 499) and GSE65858 (n = 270) cohorts [10].